Investor Alert

EyePoint Pharmaceuticals Inc.



After Hours

 --Quotes are delayed by 20 min

Sep 22, 2023, 7:30 p.m.





0.00 0.00%


Volume 8,897

Quotes are delayed by 20 min


Previous close

$ 8.35

$ 8.45


+0.10 +1.20%

Day low

Day high




52 week low

52 week high




John Barry Landis

Presently, John Barry Landis occupies the position of President for Exelead, Inc. He is also on the board of EyePoint Pharmaceuticals, Inc. and Symphogen An and Member-Chemistry Leadership Council at Purdue University.

In his past career he occupied the position of Chairman of Inotiv, Inc., Vice President at Pharmacia & Upjohn, Inc., Senior Vice President-Pharmaceutical Sciences at Schering-Plough Corp., Senior Vice President-Preclinical Development at The Upjohn Co., Senior Vice President-Preclinical Development at Pharmacia Corp. and Advisory Board at Southwest Michigan First (Venture Capital).

John Barry Landis received a graduate degree and a doctorate from Purdue University and an undergraduate degree from Kent State University (Ohio).


Date Shares Transaction Value
05/13/2019 40,000   Acquisition at $1.74 per share. 69,600

Officers and Executives

Dr. Jay S. Duker
President, Chief Executive Officer & Director
Mr. George O. Elston
CFO & Head-Corporate Development
Dr. Said Saim
Chief Technology Officer
Dr. Dario A. Paggiarino
Chief Medical Officer & Senior Vice President
Ms. Jennifer Leonard
Chief People Officer & Senior Vice President-IT
Mr. Scott Jones
Chief Commercial Officer & Senior Vice President
Mr. Michael C. Pine
Chief Corporate Development & Strategy Officer
Mr. Ye Liu
Mr. Ron I. Honig
Secretary, Chief Legal Officer & Senior VP
Ms. Isabelle Lefebvre
Chief Regulatory Officer
Dr. Göran Albert Torstensson Ando
Non-Executive Chairman
Ms. Wendy F. DiCicco
Independent Director
Dr. Anthony P. Adamis
Independent Director
Ms. Karen L. Zaderej
Independent Director
Dr. John Barry Landis
Independent Director
Dr. David R. Guyer
Independent Director
Link to MarketWatch's Slice.